EUVIMEDOpdag EUVIMED
Multizentrische StudieOpen access · CC BY-NC-ND 4.0

Effects of Velagliflozin in 8 Cats With Diabetes Mellitus and Hypersomatotropism

Francesca Del Baldo iD, Andrea Corsini iD, Francesca Bresciani, Valeria Pergolese, Isabella Tirelli iD, Antonio Maria Tardo iD, Federico Fracassi iD

Journal of Veterinary Internal Medicine · 2025

DOI: 10.1111/jvim.70222 ↗

At a glance

Multizentrische Studie in Journal of Veterinary Internal Medicine, 2025. Written by Francesca Del Baldo and 6 co-authors. Institution: Department of Veterinary Medical Sciences, Alma Mater Studiorum-University of Bologna, Bologna, Italy. Major MEDLINE topics: Cat Diseases, Diabetes Mellitus, Sodium-Glucose Transporter 2 Inhibitors, Hypoglycemic Agents. Cited 2 times so far (Crossref); 41 references. The full text is freely available (open access, CC BY-NC-ND 4.0). Funded by: Open access publishing facilitated by Universita degli Studi di Parma, as part of the Wiley - CRUI-CARE agreement..

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Background

Velagliflozin is a sodium-glucose cotransporter 2 inhibitor licensed for the treatment of diabetes mellitus (DM) in cats, but its use in cats with hypersomatotropism is not described. Hypothesis/Objectives To describe the use of velagliflozin in cats with DM and hypersomatotropism. Animals Eight client-owned cats with DM and hypersomatotropism treated with velagliflozin.

Methods

Retrospective multicentric case series. Clinical data, including diabetic clinical score, insulin dose, and continuous glucose monitoring-derived metrics were compared between the last follow-up before velagliflozin introduction (T0) and the first (T1) and last (T2) follow-ups after velagliflozin introduction.

Results

Diabetic clinical score improved in 6/8 cats after velagliflozin initiation. Median daily insulin dose decreased from 1.9 U/kg (range 0.8–7.1) at T0 to 0.5 U/kg (0–2.3) at T1 (median difference [MD] = −1.2 U/kg; 95% CI: −5.2 to 0.5; p = 0.02). Mean glucose was lower both at T1 (207 mg/dL, 96–326) and T2 (273 mg/dL, 155–350) than at T0 (435 mg/dL, 298–477; MD = −177 mg/dL, 95% CI: −238 to −92, p = 0.008 and MD = −113 mg/dL, 95% CI: −280 to −18, p = 0.03, respectively). Percentage of time in range was higher at T1 (71%, 21–98) and T2 (41%, 14–100) than at T0 (3%, 0–32; MD = 61%, 95% CI: 21 to 80, p = 0.008 and MD = 34%, 95% CI: 2 to 98, p = 0.03, respectively). Velagliflozin allowed for insulin discontinuation in two cats. One cat developed diabetic ketoacidosis on day 143, and one cat had acute kidney injury. Conclusions and Clinical Importance Velagliflozin improved diabetic control in cats with DM and hypersomatotropism, either in combination with insulin or as monotherapy.

Subjects

MeSH terms (MEDLINE)

Cat DiseasesDiabetes MellitusSodium-Glucose Transporter 2 InhibitorsHypoglycemic AgentsBridged Bicyclo Compounds, HeterocyclicGlucosidesAnimalsCatsRetrospective StudiesMaleFemaleInsulinBlood Glucose

Author keywords

SGLT2 inhibitors acromegalycontinuous glucose monitoringdiabetic ketoacidosisinsulin‐resistancemean glucose

Substances

InsulinSodium-Glucose Transporter 2 InhibitorsBlood GlucoseHypoglycemic AgentsBridged Bicyclo Compounds, HeterocyclicGlucosides

Authors and institutions

  • Department of Veterinary Medical Sciences, Alma Mater Studiorum-University of Bologna, Bologna, Italy.
  • Department of Veterinary Science, University of Parma, Parma, Italy.
  • Vet Hospital H24, VetPartners Italia, Florence, Italy.

ORCID profiles: Francesca Del Baldo, Andrea Corsini, Isabella Tirelli, Antonio Maria Tardo, Federico Fracassi

Funding

  • Open access publishing facilitated by Universita degli Studi di Parma, as part of the Wiley - CRUI-CARE agreement.

Cite

APA

Del Baldo, F., Corsini, A., Bresciani, F., Pergolese, V., Tirelli, I., Tardo, A. M., & Fracassi, F. (2025). Effects of Velagliflozin in 8 Cats With Diabetes Mellitus and Hypersomatotropism. Journal of Veterinary Internal Medicine. https://doi.org/10.1111/jvim.70222

Vancouver

Del Baldo F, Corsini A, Bresciani F, Pergolese V, Tirelli I, Tardo AM, et al. Effects of Velagliflozin in 8 Cats With Diabetes Mellitus and Hypersomatotropism. Journal of Veterinary Internal Medicine. 2025. doi:10.1111/jvim.70222

BibTeX
@article{DelBaldo2025,
  author = {Del Baldo, Francesca and Corsini, Andrea and Bresciani, Francesca and Pergolese, Valeria and Tirelli, Isabella and Tardo, Antonio Maria and Fracassi, Federico},
  title = {Effects of Velagliflozin in 8 Cats With Diabetes Mellitus and Hypersomatotropism},
  journal = {Journal of Veterinary Internal Medicine},
  year = {2025},
  doi = {10.1111/jvim.70222}
}
Start for free →